Role of bone-forming agents in the management of osteoporosis

Recent evidence confirms the superiority of osteoanabolic therapy compared to anti-remodeling drugs for rapid improvement in bone density and fracture risk reduction, providing strong justification for the use of these anabolic agents as the initial therapy in high-risk patients, to be followed by anti-remodeling therapy. This review will highlight the results of recent studies and define the current status of osteoanabolic therapy for osteoporosis.

Automated summary

Recent evidence supports the use of osteoanabolic therapy over anti-remodeling drugs for improving bone density and reducing fracture risk rapidly, especially in high-risk patients. This review discusses the latest research findings and the current status of osteoanabolic therapy for osteoporosis.